COMP <GO>
ANIP vs UNH // REVENUE GROWTH (YOY)
ANI Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ANIP 7
— UNH 5
▲ REVENUE GROWTH (YOY) LEADER: ANIP
LAST: $73.16 (+2.02%) • MKT CAP: $1.68B
revenue-growth
43.80%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIP VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIP | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | 11.47% | +4.53 | ANIP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.7x | 16.4x | -2.75 | ANIP | /valuation <GO> |
| Free Cash Flow Yield | 10.20% | 6.48% | +3.72 | ANIP | /fcf-yield <GO> |
| Operating Margin | 12.60% | 4.82% | +7.78 | ANIP | /operating-margins <GO> |
| Net Profit Margin | 8.80% | 3.14% | +5.66 | ANIP | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 43.80% | 6.46% | +37.34 | ANIP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.07% | 2.28% | -2.21 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.36 | 3.12 | -0.76 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ANIP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.7 | 59.2 | -7.50 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.1x | 17.7x | +0.36 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.68B | $368.83B | -$367.15B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIP REV | UNH REV | ANIP GROSS % | UNH GROSS % | ANIP FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $883.4M | $447.57B | — | 88.7% | $171.4M | $16.07B |
| FY 2024 | $614.4M | $400.28B | — | 88.3% | $47.8M | $20.70B |
| FY 2023 | $486.8M | $371.62B | — | 89.6% | $119.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIP // BETA —
UNH // BETA 0.33